Physical and digital books, media, journals, archives, and databases.
Results include
  1. Cancer therapeutics [digital] : experimental and clinical agents

    Totowa, N.J. : Humana, ©1997.

    This comprehensive review of existing and potential anticancer drugs and therapies by leading researchers from academia, government laboratories, and pharmaceutical companies offers essential insight into what has been accomplished and where the experimental therapy of cancer is going. The authoritative contributors illuminate the current status of the major molecules of cancer treatment, ranging from the nitrogen mustards through platinum complexes to interferons, cytokines, growth factors and their inhibitors, and on to immunotoxins, antisense oligonucleotides, and gene therapy. A companion volume by the same editor (Anticancer Drug Development Guide: Preclinical and Clinical Screening and Approval) details the processes by which new anticancer drugs are approved. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.

    Online link.springer.com

  2. Cancer therapeutics : experimental and clinical agents

    Totowa, N.J. : Humana, ©1997.

    This comprehensive review of existing and potential anticancer drugs and therapies by leading researchers from academia, government laboratories, and pharmaceutical companies offers essential insight into what has been accomplished and where the experimental therapy of cancer is going. The authoritative contributors illuminate the current status of the major molecules of cancer treatment, ranging from the nitrogen mustards through platinum complexes to interferons, cytokines, growth factors and their inhibitors, and on to immunotoxins, antisense oligonucleotides, and gene therapy. A companion volume by the same editor (Anticancer Drug Development Guide: Preclinical and Clinical Screening and Approval) details the processes by which new anticancer drugs are approved. These two volumes in the Cancer Drug Discovery and Development series reveal how and why molecules become anticancer drugs and thus offer a blueprint for the present and the future of the field.Cancer drug discovery has been and continues to be a process of ingenuity, serendip ity, and dogged determination. In an effort to develop and discover better therapies against cancer, investigators all over the world have increased our knowledge of cell biology, biochemistry, and molecular biology. The goal has been to define therapeuti cally exploitable differences between normal and malignant cells. The result has been an increased understanding of cellular and whole-organism biology and an increased respect for the flexibility and resiliency ofbiologically systems. Thus, as some new therapeutic targets have been defined and new therapeutic strategies have been attempted, so have some new biological hurdles resulting from tumor evasion of the intended therapeutic attack been discovered. Historically, anticancer drugs have originated from all available chemical sources. Synthetic molecules from the chemical industry, especially dyestuffs and warfare agents, and natural products from plants, microbes, and fungi have all been potential sources of pharmaceuticals, including anticancer agents. There is no shortage of molecules; the challenge has been and continues to be methods of identifying molecules that have the potential to be therapeutically important in human malignant disease. "Screening" remains the most important and most controversial method in cancer drug discovery. In vitro screens have generally focused on cytotoxicity and have identified several highly cytotoxic molecules. Other endpoints available in vitro are inhibition of proliferation, 3 inhibition of [ H]thymidine incorporation into DNA and various viability assays, based most frequently on dye exclusion or metabolism.

    Online SpringerLink

  3. Conn's biological stains : a handbook of dyes, stains and fluorochromes for use in biology and medicine

    10th ed. - Oxford, UK : Published for the Biological Stain Commission by BIOS Scientific Publishers, 2002.

    Published on behalf of the Biological Stain Commission For 75 years Conn's Biological Stains has been a standard reference for all those who used dyes and colorants in the biological and medical sciences. This long awaited tenth edition appears 25 years after R.D. Lillie's ninth and has been completely rewritten to reflect the increase in range of uses. Although the staining of microscopical preparations continues to expand the uses of dyes and fluorochromes now extend far beyond this traditional application. This book provides the first critical overview of the whole range of low molecular weight fluorescent probes, outside the catalogue literature. The first ten chapters are essays, by leading experts, on the important aspects of colorants and their uses. Most of the remainder of the book consists of descriptions by Dr Horobin of the properties and recent applications of hundreds of individual compounds, in about twenty chemical classes. The last chapter reviews the procedures employed at the Biological Stain Commission's laboratory to assay and test dyes and certify them as suitable for their intended applications.

Guides

Course- and topic-based guides to collections, tools, and services.
No guide results found... Try a different search

Library website

Library info; guides & content by subject specialists
No website results found... Try a different search

Exhibits

Digital showcases for research and teaching.
No exhibits results found... Try a different search

EarthWorks

Geospatial content, including GIS datasets, digitized maps, and census data.
No earthworks results found... Try a different search

More search tools

Tools to help you discover resources at Stanford and beyond.